To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Inclusion Criteria:

• The age of signing the informed consent is 18-75 years old, regardless of gender.

• Meet the 2014 American Academy of Dermatology (AAD) standards, diagnosed as AD.

• During screening and baseline visit, eczema area and severity score (EASI) ≥16points; Investigator global score (IGA) ≥3 points; Affected body surface area (BSA) ≥10%; Baseline pruritus Peak Value Scale (NRS) weekly mean ≥4 points.

• Have received at least 4 weeks of strong action or at least 2 weeks of supereffective external glucocorticoid (TCS) treatment or sufficient duration of systemicglucocorticoid treatment, the efficacy is not sufficient; Or subjects cannot receivethe above treatment due to adverse reactions or potential risks.

Exclusion Criteria:

• Used immunosuppressants/immunomodulatory drugs, ultraviolet phototherapy, systemicChinese medicine treatment within 4 weeks before randomization.

• Received topical calcineurin inhibitors (TCS), topical calcineurin inhibitors (TCI),and other topical preparations within 2 weeks before randomization.

• Received anti-interleukin-4 receptor alpha (IL-4R) monoclonal antibodies, anti-igemonoclonal antibodies, or other biologic agents within 12 weeks or 5 half-lives (whichever is longer) prior to randomization.

• Had received live attenuated vaccine within 12 weeks prior to randomization orplanned to receive it during the study period.

• Use of antihistamines within 1 week prior to randomization (unless you have receivedsteady doses of antihistamines for at least 7 days).

• Received allergen specific immunotherapy within 6 months before randomization.

• There are skin comorbidities that may interfere with study evaluation.

• There is a history of clinically significant illness that the investigator believesposes a risk to the safety of the subject and is poorly controlled.

• A known or suspected history of immunosuppression (immune deficiency).

• Subjects with any type of active malignancy or a history of malignancy (exceptcervical cancer or non-metastatic cutaneous squamous cell carcinoma, basal cellcarcinoma, and papillary thyroid carcinoma that have been cured for more than 5years prior to the screening period).

• Subject may have active Mycobacterium tuberculosis infection.

• Subjects with severe liver and kidney function impairment.

• Screening period HIV antibody positive, or have a history of HIV infection.

• Screening period of treponema pallidum antibody positive.

• Participated in clinical trials of other drugs or medical devices within 12 weeksprior to randomization.

• Treatment-requiring infections were present in the 4 weeks prior to randomization.

• During the study period, subjects plan to undergo major surgical operations.

• Pregnant or lactating women.

• Alcohol, drug abuse and known drug dependence.

• History of atopic keratoconjunctivitis with corneal involvement.

• The subject has any medical or psychiatric symptoms that interfere withparticipation in the study or with the interpretation of the study results.